See more : Yibin Tianyuan Group Co., Ltd. (002386.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Helius Medical Technologies, Inc. (HSDT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Helius Medical Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Prysmian S.p.A. (PRYMY) Income Statement Analysis – Financial Results
- XP Inc. (XPVVV) Income Statement Analysis – Financial Results
- Jiangsu Holly Corporation (600128.SS) Income Statement Analysis – Financial Results
- Ajia Innogroup Holdings, Ltd. (AJIA) Income Statement Analysis – Financial Results
- Veritone, Inc. (VERI) Income Statement Analysis – Financial Results
Helius Medical Technologies, Inc. (HSDT)
About Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 644.00K | 787.00K | 522.00K | 661.00K | 1.50M | 478.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 583.00K | 463.00K | 298.00K | 388.00K | 846.00K | 0.00 | 0.00 | 0.00 | 171.78K | 0.00 | 0.00 |
| Gross Profit | 61.00K | 324.00K | 224.00K | 273.00K | 650.00K | 478.00K | 0.00 | 0.00 | -171.78K | 0.00 | 0.00 |
| Gross Profit Ratio | 9.47% | 41.17% | 42.91% | 41.30% | 43.45% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.94M | 4.26M | 5.99M | 4.58M | 8.06M | 9.94M | 14.39M | 4.72M | 3.83M | 171.78K | 4.25M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.21M | 8.47M | 5.65M | 4.26M | 895.50K | 4.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 774.40K | 0.00 | 0.00 |
| SG&A | 9.27M | 10.64M | 12.18M | 9.71M | 16.52M | 17.21M | 8.47M | 5.65M | 5.04M | 895.50K | 4.27M |
| Other Expenses | 276.00K | 181.00K | 200.00K | 363.00K | 64.00K | 63.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.49M | 15.08M | 18.37M | 14.66M | 24.65M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Cost & Expenses | 13.07M | 15.55M | 18.66M | 15.05M | 25.49M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Interest Income | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 111.00K | 20.07K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 1.95M | 5.17M | 1.67M | 176.49K | 0.00 | 0.00 |
| Depreciation & Amortization | 162.00K | 306.00K | 374.00K | 482.00K | 191.00K | 59.00K | 17.00K | 1.78M | 20.07K | 0.00 | 0.00 |
| EBITDA | -12.11M | -14.50M | -17.82M | -13.90M | -23.93M | -26.62M | -17.67M | -8.60M | -6.83M | -1.07M | -8.52M |
| EBITDA Ratio | -1,879.97% | -2,044.73% | -3,439.08% | -2,132.68% | -2,535.09% | -5,147.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.43M | -14.76M | -18.14M | -14.39M | -24.00M | -26.68M | -22.85M | -10.37M | -8.86M | -1.07M | -8.52M |
| Operating Income Ratio | -1,929.81% | -1,875.35% | -3,475.48% | -2,176.40% | -1,604.01% | -5,580.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.58M | 687.00K | 10.00K | 72.00K | 14.22M | -1.95M | -5.17M | -1.67M | 1.98M | 0.00 | 0.00 |
| Income Before Tax | -8.85M | -14.07M | -18.13M | -14.13M | -9.78M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | -8.52M |
| Income Before Tax Ratio | -1,374.22% | -1,788.06% | -3,473.56% | -2,137.67% | -653.81% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.51M | -10.00K | -193.00K | -14.12M | 3.96M | 10.34M | 1.67M | -146.62K | 0.00 | -8.52M |
| Net Income | -8.85M | -12.56M | -18.12M | -13.94M | 4.34M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | 0.00 |
| Net Income Ratio | -1,374.22% | -1,595.68% | -3,471.65% | -2,108.47% | 290.04% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| EPS Diluted | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program
-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS ® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) --...
Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis
PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans
Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk
New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps
Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
NEWTOWN, Pa., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective December 27, 2022, its independent directors approved an equity award under...
5 Winning Stocks Backed by the Overlooked Rising P/E Trick
Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).
Helius Medical Technologies, Inc. (HSDT) Moves to Buy: Rationale Behind the Upgrade
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Helius Medical Technologies, Inc. (HSDT) Q3 2022 Earnings Call Transcript
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Dane Andreeff - President & Chief Executive Officer Jeff Mathiesen - Chief Financial Officer Conference Call...
Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results
-- Total Q3 revenue up 80% over prior year -- -- Cash on hand expected to fund operations through 2023 -- -- Company to host call at 8:30am today -- NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical...
Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer and MGH Institute of Health Professions to its Therapeutic Experience Program
-- Fourth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects' adherence to PoNS® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Helius Medical...
Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program
-- Third Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS® therapy for gait improvement in Multiple Sclerosis -- -- Third Center of Excellence added in multi-center, company-sponsored,...
Source: https://incomestatements.info
Category: Stock Reports